Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.49 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.46 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.46 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.44 |
| ▸ | DPP4 | P27487 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30778326 | 0.89 | NAMPT (0.54) | NAMPTKDM4EMAPTTHRBPDE4B | |
| SCHEMBL15157112 | 0.89 | NAMPT (0.54) | NAMPTKDM4EMAPTTHRBPDE4B | |
| SCHEMBL25228900 | 0.88 | NAMPT (0.51) | NAMPTKDM4EMAPTTHRBPDE4B | |
| SCHEMBL15174834 | 0.88 | PDE4B (0.46) | NAMPTKDM4EPDE4B | |
| SCHEMBL12479918 | 0.86 | NAMPT (0.52) | NAMPTKDM4EMAPTTHRBPDE4B | |
| SCHEMBL24793972 | 0.86 | NAMPT (0.52) | NAMPTKDM4EMAPTTHRBPDE4B | |
| SCHEMBL25539754 | 0.86 | PDE4B (0.53) | NAMPTKDM4EMAPTTHRBPDE4B | |
| SCHEMBL29976347 | 0.85 | KDM4E (0.53) | NAMPTKDM4EMAPTTHRBPDE4B | |
| SCHEMBL15376723 | 0.85 | KDM4E (0.53) | NAMPTKDM4EMAPTTHRBPDE4B | |
| SCHEMBL15862956 | 0.85 | NAMPT (0.51) | NAMPTKDM4EMAPTTHRBPDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006113458-A1 | HETEROCYCLIC INHIBITORS OF PROTEIN ARGININE METHYL TRANSFERASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-10-26 | — | — | WO | disclosed |
| US-20060235037-A1 | Heterocyclic inhibitors of protein arginine methyl transferases | BRISTOL-MYERS SQUIBB COMPANY | 2006-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060235037-A1 | Heterocyclic inhibitors of protein arginine methyl transferases | PRMT1, PRMT3, PRMT8 | NAMPT 404/4885KDM4E 646/4885MAPT 150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.